Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01521676 | Predictive Clinical and Biological Parameters in Breast Cancer(BC-BIO) | N/A | terminated | Jan 31, 2012 | Institut Paoli-Calmettes | strategical decision | Sponsor / business decision |
| NCT01589861 | Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated,…(PIKHER2) | Phase 1 / Phase 2 | terminated | May 2, 2012 | Institut Paoli-Calmettes | Drug development withdrawn | Other (stated, no rule matched) |
| NCT01980277 | Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic…(TAKTIC) | Phase 1 / Phase 2 | terminated | Nov 8, 2013 | Institut Paoli-Calmettes | Drug development stopped | Other (stated, no rule matched) |
| NCT02525211 | Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy :… | Phase 3 | terminated | Aug 17, 2015 | Institut Paoli-Calmettes | Recruitment defect | Enrollment / accrual |
| NCT02856503 | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors | Phase 1 / Phase 2 | withdrawn | Aug 5, 2016 | Eli Avisar, MD | Lack of Funding | Funding |
| NCT05488145 | A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer… | N/A | terminated | Aug 4, 2022 | Emory University | Insufficient Staff | Other (stated, no rule matched) |
| NCT07475923 | Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad… | — | withdrawn | Mar 17, 2026 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT02095184 | GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients | N/A | terminated | Mar 24, 2014 | University of Maryland, Baltimore | This study was terminated due to slow accrual, and this due to the changing practice patterns, and… | Enrollment / accrual |
| NCT07140965 | The Impact of Surgeon-Interpreted Intraoperative Margin Assessment During Breast… | — | suspended | Aug 26, 2025 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT00802711 | 3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After… | N/A | terminated | Dec 5, 2008 | Cancer Trials Ireland | Slow accrual | Enrollment / accrual |
| NCT05744375 | Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients…(TRANSCENDER) | Phase 2 | terminated | Feb 27, 2023 | Spanish Breast Cancer Research Group | The study stopped due to insufficient accrual (only two patients were included), and the sponsor… | Enrollment / accrual |
| NCT04791384 | Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to… | Phase 1 / Phase 2 | terminated | Mar 10, 2021 | Criterium, Inc. | Study was terminated due to delayed recruitment. | Enrollment / accrual |
| NCT05547347 | Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With… | — | suspended | Sep 21, 2022 | Mayo Clinic | Pending biocompatibility testing | Other (stated, no rule matched) |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT04877912 | Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening | — | terminated | May 7, 2021 | University of Chicago | Funding obstacles | Funding |
| NCT01780064 | Psychosocial Support to Facilitate the Return to Employment of Women With Breast Cancer(APAPI) | N/A | terminated | Jan 30, 2013 | Centre Oscar Lambret | Lack of enrollment | Enrollment / accrual |
| NCT02570100 | Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem…(RepriM) | N/A | terminated | Oct 7, 2015 | Centre Oscar Lambret | The failures of the culture and immunostaining techniques for ALDH do not allow the main objective… | Other (stated, no rule matched) |
| NCT04202640 | Mechanical Stimulation on Pain Level and Functional Discomfort After Breast Cancer Surgery(PRESSODOU) | N/A | terminated | Dec 17, 2019 | Centre Oscar Lambret | insufficient recruitment | Enrollment / accrual |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Phase 1 / Phase 2 | terminated | Mar 9, 2021 | M.D. Anderson Cancer Center | Insufficient accrual | Enrollment / accrual |
| NCT01614704 | Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility | — | terminated | Jun 8, 2012 | Centre Oscar Lambret | End of study | Other (stated, no rule matched) |
| NCT05742269 | Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative…(MIMIR-mTNBC) | — | terminated | Feb 23, 2023 | Karolinska University Hospital | Slow patient accrual; decreasing use of IMP. | Enrollment / accrual |
| NCT04796324 | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the… | Phase 2 | terminated | Mar 12, 2021 | Allarity Therapeutics | Company Decision | Sponsor / business decision |
| NCT06229392 | A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With… | Phase 1 | withdrawn | Jan 29, 2024 | Rush University Medical Center | Internal operational issues prevented the study site from opening to enrollment. | Enrollment / accrual |
| NCT03868475 | Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline…(VAPEX) | N/A | withdrawn | Mar 11, 2019 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Publication of only protocol desired | Other (stated, no rule matched) |
| NCT05554354 | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in… | Phase 2 | terminated | Sep 26, 2022 | National Cancer Institute (NCI) | Other - slow accrual | Enrollment / accrual |
| NCT06315296 | An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing… | N/A | terminated | Mar 18, 2024 | Thomas Jefferson University | slow accrual | Enrollment / accrual |
| NCT03953326 | HeartPhone Cancer Survivors Trial 2019 | Phase 1 / Phase 2 | terminated | May 16, 2019 | Penn State University | Futility in recruitment | Efficacy / futility |
| NCT07439432 | Stereotactic Guided Biopsy and Cryoablation | N/A | withdrawn | Feb 27, 2026 | Montefiore Medical Center | Study never approved by the Albert Einstein College of Medicine IRB. | Other (stated, no rule matched) |
| NCT03801369 | AMTEC IIT: Phase 2 Multiarm Study in TNBC | Phase 2 | terminated | Jan 11, 2019 | Gordon Mills, MD, PhD | loss of funding | Funding |
| NCT03428581 | Preventing Lymphedema in Axillary Lymph Node Dissection | N/A | terminated | Feb 9, 2018 | Mayo Clinic | slow accrual; diminished funding | Enrollment / accrual |
| NCT05014295 | Patient Recall of Cancer Screening and Diagnosis | N/A | withdrawn | Aug 20, 2021 | Case Comprehensive Cancer Center | Staffing unavailability | Other (stated, no rule matched) |
| NCT03130439 | Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast… | Phase 2 | terminated | Apr 26, 2017 | Dana-Farber Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT05269160 | Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ) | Phase 1 / Phase 2 | terminated | Mar 7, 2022 | Baylor College of Medicine | PI is leaving institution and this protocol will not be further pursued at this institution. | Other (stated, no rule matched) |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination… | Phase 1 / Phase 2 | terminated | Apr 5, 2017 | M.D. Anderson Cancer Center | \<75% accrued | Enrollment / accrual |
| NCT04504331 | Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2… | Phase 1 | terminated | Aug 7, 2020 | Jennifer Lee Caswell-Jin | Drug manufacturer decision to terminate development. | Drug supply |
| NCT06585969 | A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal…(DISCORDANT) | Phase 3 | withdrawn | Sep 19, 2024 | Danish Breast Cancer Cooperative Group | Lack of funding | Funding |
| NCT03237572 | Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer(Breast-48) | Phase 1 | terminated | Aug 2, 2017 | Patrick Dillon, MD | Low rate of enrollment | Enrollment / accrual |
| NCT04990895 | A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys | N/A | terminated | Aug 5, 2021 | AHS Cancer Control Alberta | Slow study accrual. Study sponsor decided to terminate the study in consultation with the DSMB. | Enrollment / accrual |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High… | N/A | withdrawn | Nov 10, 2025 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT04491864 | DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation(DWIBS) | — | terminated | Jul 29, 2020 | Baylor Research Institute | Further funding was not approved for this study | Funding |
| NCT04095689 | Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple…(INTEGRAL) | Phase 2 | terminated | Sep 19, 2019 | The Methodist Hospital Research Institute | Stopping rules met per protocol, trial will be terminated | Other (stated, no rule matched) |
| NCT03289039 | Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | Phase 2 | terminated | Sep 20, 2017 | Dana-Farber Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With…(neoMono) | Phase 2 | terminated | Feb 25, 2021 | Palleos Healthcare GmbH | The trial stopped recruitment prematurely after a first planned interim analysis of the first 100… | Efficacy / futility |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT04578106 | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2…(ELPIS) | Phase 2 | terminated | Oct 8, 2020 | Fundacio Clinic Barcelona | The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize… | Enrollment / accrual |
| NCT05803889 | Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast…(PROTECT-COEUR) | — | terminated | Apr 7, 2023 | Institut de cancérologie Strasbourg Europe | The PROTECT-COEUR study had to be stopped primarily due to logistical constraints. | Other (stated, no rule matched) |
| NCT06408168 | Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone… | Phase 2 | terminated | May 10, 2024 | M.D. Anderson Cancer Center | \<75% Participation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 21, 2026source: clinicaltrials